Merck shares drop 10% as pharma giant scraps trial of promising cancer drug

Read Time:8 Second

Merck & Co called off a Phase III trial of its promising cancer drug Xevinapant after an independent panel concluded it is unlikely to meet its goals

About Post Author

Happy

0 %

Sad

0 %

Excited

0 %

Sleepy

0 %

Angry

0 %

Surprise

0 %

Michelle Bowman was the first Federal Reserve governor to dissent from an interest-rate decision since 2005.

Micron shares have shed most of their 2024 gains, but memory pricing could improve in the coming months, Citi says.

That’s in part because most of his $700 million contract is deferred. Still, his stats this season are worth over...

JPMorgan Chase CEO Jamie Dimon suggests the half-point interest-rate cut is “a minor thing” that Wall Street — not Main...

Also: What to expect for loan interest rates, how Social Security survivor and spousal benefits work, and advice from the...

Constellation Energy said Friday it plans to restart a nuclear reactor at Three Mile Island.